Oropouche Fever

Oropouche fever is an acute zoonotic and urban-amplified arboviral disease caused by Oropouche virus (OROV; species Orthobunyavirus oropoucheense), an enveloped, tri-segmented negative-sense RNA virus belonging to the Simbu serogroup within the genus Orthobunyavirus, family Peribunyaviridae. First isolated in 1955 by Charles R. Anderson and colleagues at the Trinidad Regional Virus Laboratory from the blood of a 24-year-old febrile forest charcoal worker in Vega de Oropouche, Trinidad, and subsequently recovered in 1960 from a pale-throated three-toed sloth (Bradypus tridactylus) and Ochlerotatus (Aedes) serratus mosquitoes along the Belém–Brasília highway in Pará State, Brazil, Oropouche fever has caused more than 30 major epidemics and an estimated half-million human infections across the Amazon Basin, the Guiana Shield, and Panama. Historically regarded as a self-limiting, dengue-mimicking febrile illness confined to Amazonian forest-edge towns, the emergence of a novel reassortant OROV lineage in 2023–2024 drove pan-South American geographic expansion, adult fatalities, and confirmed vertical maternal-fetal transmission resulting in fetal demise and congenital microcephaly.

Tri-Segmented Bunyavirus Architecture

Mature Oropouche virus particles are spherical, lipid-enveloped virions measuring 80 to 110 nm in diameter. The viral genome is divided into three single-stranded, negative-sense (or ambisense) RNA segments flanked by conserved 3′ and 5′ terminal panhandle sequences that circularize each ribonucleoprotein complex:

• Large (L) segment (~6.8 kb): Encodes the viral RNA-dependent RNA polymerase (RdRp, ~2,250 amino acids), responsible for cap-snatching transcription and genome replication in the host cytoplasm.
• Medium (M) segment (~4.4 kb): Encodes a glycoprotein precursor polyprotein co-translationally cleaved in the endoplasmic reticulum into two surface envelope glycoproteins (Gn and Gc, which assemble into heterodimeric spikes mediating host-cell attachment via low-density lipoprotein receptor-related protein 1 [LRP1] and low-pH endosomal fusion) and the non-structural protein NSm.
• Small (S) segment (~0.95 kb): Encodes the nucleocapsid protein (N) and, in an overlapping +1 reading frame, the non-structural protein NSs, a potent virulence factor that inhibits host RNA polymerase II phosphorylation and blocks type I interferon (IFN-α/β) transcription.

Segment Reassortment within the Simbu Serogroup

Because the OROV genome comprises three discrete RNA segments, co-infection of a single vertebrate cell or arthropod midgut cell by two distinct Simbu serogroup orthobunyaviruses permits genetic reassortment—the exchange of intact L, M, or S segments to generate progeny viruses with altered antigenic surfaces and enhanced replication fitness. Across South America, wild OROV strains have repeatedly donated their L and S segments to acquire divergent M segments from related orthobunyaviruses, generating recognized natural reassortants including Iquitos virus (IQTV, identified in Loreto, Peru in 1999), Madre de Dios virus (MDDV, Peru and Venezuela), and Perdoes virus (Minas Gerais, Brazil). In 2022–2024, genomic surveillance by Felipe Naveca and colleagues demonstrated that the surging pan-Amazonian epidemic strain (OROV_BR-2015-2024) arose from a homologous recombination/reassortment event uniting an M segment related to virus circulating in the eastern Amazon (2009–2018) with L and S segments derived from the Iquitos/Peruvian-Colombian clade, conferring higher viral plaque titers and accelerated replication kinetics in mammalian cells.

Oropouche fever is maintained across tropical and subtropical South America through two interconnected ecological cycles linked by human movement across forest boundaries:

Role of Culicoides paraensis and Culex quinquefasciatus

Unlike dengue fever or Mayaro fever, the primary epidemic vector of Oropouche fever in human settlements is not a mosquito but the minute hematophagous biting midge Culicoides paraensis (order Diptera, family Ceratopogonidae), known locally in Brazil as maruim or mosquito-pólvora. Measuring only 1.0 to 1.5 mm in body length, female C. paraensis midges readily pass through standard 1.2-mm window screens and bed-net meshes, biting humans both indoors and outdoors with peak diurnal activity during late afternoon (16:00 to 18:00 hours). Larvae of C. paraensis do not develop in open water containers; instead, they require moist, decomposing organic substrates—specifically rotting banana and plantain stalks (Musa spp.), discarded cacao pods (Theobroma cacao), cupuaçu husks (Theobroma grandiflorum), and decomposing tree holes—explaining why Oropouche epidemics flourish in agroforestry belts and peri-urban Amazonian neighborhoods. The domestic mosquito Culex quinquefasciatus acts as a secondary urban vector capable of nocturnal human-to-human transmission when human viremia is elevated, although its midgut infection threshold is substantially higher than that of C. paraensis.

Acute Dengue-Like Syndrome and the 60% Relapse Signature

Following a bite from an infected midge and an intrinsic incubation period of 3 to 8 days, symptomatic Oropouche fever begins abruptly with high fever (39.0 to 40.0 °C), chills, intense generalized or retro-orbital headache, photophobia, dizziness, lumbar and calf myalgia, polyarthralgia, anorexia, nausea, and vomiting. Conjunctival injection, transient rubelliform or maculopapular rash on the trunk and arms, and minor mucosal bleeding (epistaxis, gingival bleeding, or petechiae) occur in 5 to 15 percent of patients, accompanied by leukopenia and mild thrombocytopenia that closely mimic acute dengue fever and Mayaro fever.

While the initial febrile episode resolves spontaneously within 2 to 5 days, a distinguishing clinical feature of Oropouche fever is its biphasic clinical relapse: in approximately 50 to 60 percent of patients, fever, severe headache, myalgia, and asthenia recur 1 to 2 weeks after initial defervescence. Relapse episodes last 2 to 4 days and may occur once or twice before complete recovery; whether relapses reflect reactivation of viral replication in peripheral lymphoid or neural tissues or an immune-mediated post-viral rebound remains under active investigation.

Neuroinvasive Disease and Congenital Teratogenicity

In 4 to 8 percent of hospitalized patients, Oropouche virus crosses the blood-brain barrier (or enters via neural pathways) during the first or second week of illness to cause aseptic meningitis or meningoencephalitis. Neuroinvasive Oropouche presents with nuchal rigidity, intractable headache, photophobia, diplopia, vertigo, lethargy, confusion, and cerebellar ataxia; cerebrospinal fluid (CSF) analysis reveals lymphocytic pleocytosis (15 to 500 cells/μL), elevated protein, normal glucose, and detectable OROV RNA or anti-OROV IgM. Furthermore, during the 2024 epidemic in Brazil, virological investigations confirmed that maternal OROV infection during pregnancy can cross the placenta, infecting fetal brain, liver, kidney, and spleen tissues to cause spontaneous abortion, third-trimester stillbirth, and congenital neurodevelopmental anomalies including microcephaly, ventriculomegaly, corpus callosum hypoplasia, and arthrogryposis analogous to congenital Zika syndrome.

Because Oropouche fever is clinically indistinguishable from dengue, Zika, chikungunya, and Mayaro fever during the first 72 hours, laboratory confirmation relies on real-time reverse transcription-polymerase chain reaction (RT-qPCR) targeting the conserved S segment (and M segment for lineage typing) in serum, plasma, urine, or CSF during days 1 to 5 of fever, followed from day 5 onward by IgM capture ELISA (MAC-ELISA) and plaque reduction neutralization testing (PRNT). No licensed antiviral drug or human vaccine is currently available; clinical care consists of oral or intravenous hydration and acetaminophen analgesia while avoiding aspirin and NSAIDs until dengue has been excluded. Vector control requires agricultural waste management (removing decaying banana pseudostems and cacao husks around dwellings), application of Bacillus thuringiensis israelensis or targeted chemical larvicides to organic breeding sites, installation of ultra-fine-mesh window screens (≤0.5 mm pore size) or insecticide-impregnated curtains, and personal repellent use during late-afternoon peak biting hours.

Between 2020 and 2022, genomic surveillance networks in French Guiana (specifically the remote rainforest village of Saül), Colombia, and Peru detected localized clusters of Oropouche fever in populations without Amazonian travel histories, demonstrating active extra-Amazonian circulation of Simbu serogroup orthobunyaviruses and highlighting the need for multiplex RT-qPCR screening among dengue-negative febrile cohorts (Gaillet et al., 2021).

In 2023, a novel reassortant lineage of Oropouche virus (OROV_BR-2015-2024) triggered a multi-state epidemic across the western Brazilian Amazon—beginning in Amazonas, Acre, Rondônia, and Roraima—where phylogenetic sequencing revealed that higher mammalian replication titers and partially escaped prior neutralizing immunity enabled rapid amplification in both rural agroforestry communities and major urban centers such as Manaus and Porto Velho (Naveca et al., 2024; Scachetti et al., 2024).

In 2024, the Oropouche epidemic expanded across South America and the Caribbean to surpass 10,000 laboratory-confirmed cases across Brazil (spanning 22 states, including autochthonous transmission in non-Amazonian Atlantic Forest states such as Bahia, Espírito Santo, Pernambuco, Rio de Janeiro, and Santa Catarina), Bolivia, Peru, Colombia, and Cuba. In July 2024, the Brazilian Ministry of Health and Evandro Chagas Institute documented the world's first confirmed fatal adult cases of Oropouche fever in two young women without comorbidities in Bahia who developed rapid hemorrhagic and hepatic failure mimicking fulminant dengue, alongside confirmed vertical maternal-fetal transmission cases resulting in fetal death and neonatal microcephaly with subcortical necrosis and arthrogryposis (Bandeira et al., 2024; das Neves Martins et al., 2024).

Why do standard mosquito bed nets fail to prevent Oropouche fever transmission?

The primary epidemic vector of Oropouche fever, the biting midge Culicoides paraensis, measures only 1.0 to 1.5 mm in length—less than one-third the size of an Aedes or Anopheles mosquito—allowing it to pass through standard 1.2-to-1.5-mm mosquito net meshes. In addition, C. paraensis feeds primarily during daylight and late afternoon hours (16:00–18:00) when residents are awake and outside bed nets, requiring ultra-fine mesh screens, insecticide impregnation, and agricultural breeding-site removal for effective protection.

What causes the relapse of symptoms in Oropouche fever?

Approximately 50 to 60 percent of patients with Oropouche fever experience a recurrence of high fever, headache, myalgia, and asthenia 1 to 2 weeks after their initial fever resolves. Clinical studies indicate that early resumption of physical exertion during convalescence precipitates relapse, driven by residual viral replication in peripheral tissues and secondary host inflammatory cytokine release before neutralizing antibody titers fully mature.

How did the 2023–2024 Oropouche virus lineage acquire higher epidemic potential?

Because Oropouche virus possesses a tri-segmented RNA genome (L, M, and S segments), co-infection of hosts by distinct regional strains allowed a genetic reassortment event combining the M glycoprotein segment of an eastern Amazonian lineage with the L polymerase and S nucleocapsid/NSs segments of the Peruvian-Colombian clade. Cell-culture and plaque assays demonstrated that this reassortant virus produces larger plaques, reaches higher viral loads in mammalian cells, and is less efficiently neutralized by antibodies from pre-2015 OROV infections.

1. Pinheiro, F. P., Travassos da Rosa, A. P. A., Travassos da Rosa, J. F. S., et al. (1981). Oropouche virus. I. A review of clinical, epidemiological, and ecological findings. American Journal of Tropical Medicine and Hygiene, 30(1), 149–160. doi:10.4269/ajtmh.1981.30.149
2. Travassos da Rosa, J. F., de Souza, W. M., Pinheiro, F. P., et al. (2017). Oropouche Virus: Clinical, Epidemiological, and Molecular Aspects of a Neglected Orthobunyavirus. American Journal of Tropical Medicine and Hygiene, 96(5), 1019–1030. doi:10.4269/ajtmh.16-0672
3. Gaillet, M., Pichard, C., Restrepo, J., et al. (2021). Outbreak of Oropouche Virus in French Guiana. Emerging Infectious Diseases, 27(10), 2711–2714. doi:10.3201/eid2710.204760
4. Naveca, F. G., de Almeida, T. A. P., Souza, V., et al. (2024). Human outbreaks of a novel reassortant Oropouche virus in the Brazilian Amazon region. Nature Medicine, 30, 3530–3539. doi:10.1038/s41591-024-03300-3
5. Scachetti, G. C., Forato, J., Claro, I. M., et al. (2024). Re-emergence of Oropouche virus between 2023 and 2024 in Brazil: an observational epidemiological study. The Lancet Infectious Diseases, 25(2), 166–175. doi:10.1016/S1473-3099(24)00619-400619-4)
6. Bandeira, A. C., Barbosa, A. C. N. S., Souza, M., et al. (2024). Clinical profile of Oropouche Fever in Bahia, Brazil: unexpected fatal cases. The Lancet Infectious Diseases, 24(11), e662–e663. doi:10.1016/S1473-3099(24)00505-X00505-X)
7. das Neves Martins, F. E., Chiang, J. O., Nunes, B. T. D., et al. (2024). Newborns with microcephaly in Brazil and potential vertical transmission of Oropouche virus: a case series. The Lancet Infectious Diseases, 24(11), e664–e665. doi:10.1016/S1473-3099(24)00617-000617-0)